Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2022

Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients

The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below:

(In thousands)	Three Months Ended March 31, 2022		Three Months Ended June 30, 2022
Revenue related to deferred revenue balance at beginning of period	$	36,151	$	25,901
Revenue related to new performance obligations satisfied during the period		45,306		55,990
Revenue recognized under "right-to-invoice" expedient		61,114		68,877
Reimbursed travel expenses, shipping and other revenue		101		130
Total revenue	$	142,672	$	150,898

(In thousands)	Three Months Ended March 31, 2021		Three Months Ended June 30, 2021
Revenue related to deferred revenue balance at beginning of period	$	29,401	$	36,770
Revenue related to new performance obligations satisfied during the period		47,263		41,814
Revenue recognized under "right-to-invoice" expedient		56,811		62,105
Reimbursed travel expenses, shipping and other revenue		177		517
Total revenue	$	133,652	$	141,206

Summary of Changes in Estimate of Credit Losses for Contract Assets

Changes in the estimate of credit losses for contract assets are presented in the table below.

	Six Months Ended June 30,
(In thousands)	2022			2021
Beginning balance	$	2,110		$	2,110
Write-offs		(345	)		0
Ending balance	$	1,765		$	2,110
Less: Contract assets, short-term		564			576
Total contract assets, long-term	$	1,201		$	1,534

Revenue by Segment [Member]

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segment.

	Three Months Ended June 30, 2022
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	112,678	$	6,261	$	118,939
Payer & Life Sciences		31,959		0		31,959
Total revenue	$	144,637	$	6,261	$	150,898

	Three Months Ended June 30, 2021
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	108,147	$	7,757	$	115,904
Payer & Life Sciences		25,302		0		25,302
Total revenue	$	133,449	$	7,757	$	141,206

	Six Months Ended June 30, 2022
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	224,949	$	12,655	$	237,604
Payer & Life Sciences		55,966		0		55,966
Total revenue	$	280,915	$	12,655	$	293,570

	Six Months Ended June 30, 2021
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	212,035	$	15,039	$	227,074
Payer & Life Sciences		47,784		0		47,784
Total revenue	$	259,819	$	15,039	$	274,858